In-Med launches brain quantifying analytics tool

13 January 2020 | News

NEUROShield is a cloud-based clinical decision support tool for neurological disorders

In-Med Prognostics, a Pune based health tech startup developing AI based brain health diagnostic and prognostic tools, launched NEUROShield, a cloud-based Clinical Decision Support Tool for neurological disorders. The hospitals and clinics deploying this technology stand to benefit as it leverages clinical decision support mechanisms to take early calls for preventive health. The analysis of NEUROShield enables actionable, quantitative, objective decision making to the neuro-physicians for differential diagnosis. The NeuroShield technology uses pattern recognition and deep learning for the development of clinical biomarkers for early prognosis and differential diagnosis.

In-Med Prognostics already has strategic alliances with like-minded hospitals that have agreed to collaborate and leverage the use of NEUROShield for the benefit of patients across geographies. Some of these hospitals and screening centers are Sahyadri Hospital, Deenanath Mangeshkar Hospital, Arthi diagnostic center, NM Medical, P.H diagnostic Center and Noble Hospital, among others.

NEUROShield, powered by state-of-the-art AI, utilizes 3D based MRI images to their full potential by extracting data and providing volumetric analysis for the brain and its various structures. Use of cutting edge, AI technology enables them to perform analysis, on both Indian and Caucasian brains, thus unlocking a global scalability potential for their platform.

Dr. Latha Poonamallee, Co-founder and chairperson, In-Med Prognostics, says, "I am delighted to be leading this effort in developing a global gold standard product right here in India to serve the world at large".

Rajesh Purushottam, Co-founder, InMed Prognostics, said, "The launch of NEUROShield is a step closer towards making mental health more acceptable by dissolving the stigma around it and making it more acceptable across age groups and geographies. Our aim with this initiative is to make brain screening mainstream like any other diagnostic screening available today.''

Rahul Kulkarni from Deenanath Mangeshkar Hospital in Pune, shares his opinion that, "I have started using NEUROShield in my clinical practice in patients with neurological disorders. While a traditional 2D MRI imaging provides only a limited

understanding of mild atrophy changes, NEUROShield provides differential diagnosis on visualization and volumetric analysis of 3D MRI images. This analysis could help in assessing conditions like MCI, dementia, MS, epilepsy, and TB more efficiently and arrive at optimal evidence-based clinical decisions."

In-med Prognostics, incorporated in early 2018, is committed to bringing affordable, accessible, reliable and data-driven brain health diagnostics and prognostics tools to India and other emerging markets. Their team has experts in Medical Image Analysis, Deep Learning, and Bio-Medical Engineering. The consultants and Scientific Advisory Board of In-Med Prognostics have experts from the field, including some of India's Leading Neuro-Physicians, Radiologists and Psychiatrists.

Early last year, the company received a Biotechnology Ignition Grant of Rs. 50 lakhs for a duration of 18 months from the Biotechnology Industry Research Assistance Council (BIRAC) that was used to develop technology that will label, visualize, and quantify the volumes of brain structures using 3D MRI images. Also, they were recognized globally as one of the top 50 health care companies around the world by International Forum on Advancements in Healthcare (IFAH).